The results of their experiments demonstrated that a single administration of AAV-miR-7 significantly reduced tumor volumes, upregulated DR5, and enabled SC-delivered S-TRAIL to eradicate glioblastoma xenografts generated from TRAIL-resistant patient-derived GSCs, ultimately improving the survival of mice. Here, TNFSF10 is linked to glioblastoma.